Sandoz Head Jeff George Named Top "40 Under 40"
Holzkirchen, Germany
Sandoz is pleased to announce that Jeff George, global Head of Sandoz, has been named part of Fortune Magazine’s 2011 Top “40 Under 40”.
George ranked ninth on the annual “40 under 40” list, which features Fortune’s selection of the top 40 young business leaders from a variety of industries.
In January 2007, George joined Novartis in the Vaccines and Diagnostics Division as Head of Commercial Operations for Western and Eastern Europe, and then advanced to Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS. In 2008, he was appointed to head Sandoz, where he helped lead the company to double-digit revenue growth and make significant strides with respect to its differentiated products strategy, particularly in the field of biosimilars.
See the full 2011 ranked list here: http://www.Fortune.com/40under40
About Sandoz
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), and Oriel Therapeutics (US). In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion.
For further information, please contact:
Marija Mandic
Sandoz Global Communications
+49 172 442 84 91
marija.mandic@sandoz.com
